Drug
Inupadenant clinical trials
Also written EOS100850.
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2021
How studies write it
Studies that test it under each name
Name
Development codes
Studies by the year they started
3 studies that test it; most in 2021 (2)
| Year | Studies |
|---|---|
| 2021 | 2 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 3 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses inupadenant is read from its arms, and is right about nine times in ten.
Testing it · 3
- Study of Inupadenant (EOS100850) With Chemotherapy as Second Line Treatment for Nonsquamous Non-small Cell Lung CancerActive, not recruitingPhase 2iTeos TherapeuticsNCT05403385Written as inupadenant
- New Formulation Study of Inupadenant (EOS100850) in Patients with CancerCompletedPhase 1iTeos TherapeuticsNCT05117177Written as Inupadenant
- Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid TumorsActive, not recruitingPhase 1/2iTeos Belgium SANCT05060432Written as inupadenant
Given in every arm · 1 — inupadenant is usual care beside what is tested
Codes
What other systems call inupadenant · ClinicalTrials.gg INT016796
- UNII (FDA) HQ700V0X06INUPADENANTOne source FDA
- NCI Thesaurus C172109InupadenantOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | HQ700V0X06 | INUPADENANT | One source FDA |
| NCI Thesaurus | C172109 | Inupadenant | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.